TrialEye (London, England)2017

One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration.

H Almuhtaseb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.